title: Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapy.
abstract: There have been few detailed studies conducted on the cell population in relation to cytogenetic changes between the pre- and post-treatment periods in patients with prostate cancer. We investigated numerical chromosome changes associated with anti-androgen therapy, using fluorescence in situ hybridization (FISH). FISH using chromosome-specific centromeric probes was used to assess transitional changes in the frequency of aneuploidy for chromosomes 7, 8, 10, 12, 16, X, and Y in prostate cancer during the pre- and post-treatment periods. Gains of chromosomes 7, 8 and 12 were notable in the pre-treatment samples (8 out of 9 cases in chromosome 7; 8 out of 9 cases in chromosome 8; 7 out of 9 cases in chromosome 12), while a notable reduction in the number of cells with extra copies of these chromosomes was observed in post-treatment specimens. Other chromosomes did not show noticeable change in their FISH signals at each phase of clinical treatment in all 9 cases. Changes in cell number with high ploidies of chromosome 7, 8 and 12 reflect the clinical effects of anti-androgen therapy at the early phase, which might explain the androgen dependency of metastatic prostate cancer cells.
authors.affiliation: Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kasahara
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
authors.forename: I
authors.initials: I
authors.lastname: Yamasaki
authors.forename: T
authors.initials: T
authors.lastname: Karashima
authors.forename: M
authors.initials: M
authors.lastname: Kamada
authors.forename: K
authors.initials: K
authors.lastname: Yuri
authors.forename: T
authors.initials: T
authors.lastname: Shuin
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000782:Aneuploidy; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002869:Chromosome Aberrations / Q000235:genetics; D025063:Chromosome Disorders; D002877:Chromosomes, Human / Q000235:genetics*; D002906:Chromosomes, Human, 6-12 and X / Q000235:genetics; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D012730:Sex Chromosomes / Q000235:genetics*; D014960:X Chromosome / Q000235:genetics; D014998:Y Chromosome / Q000235:genetics
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen